Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion

Full text
Author(s):
Pagliarelli Acencio, Milena Marques [1] ; Puka, Juliana [1] ; Alvarenga, Vanessa Adelia [1] ; Martins, Vanessa [2] ; Peres de Carvalho, Mariana Lombardi [3] ; Marchi, Evaldo [4] ; Capelozzi, Vera Luiza [2] ; Teixeira, Lisete Ribeiro [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Lab Pleura LIM09, Div Pneumol, Inst Coracao InCor, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Dept Patol, Fac Med, Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Lab Genet & Cardiol Mol, Inst Coracao InCor, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP - Brazil
[4] Fac Med Jundiai, Jundiai, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: ONCOTARGET; v. 8, n. 62, p. 105093-105102, DEC 1 2017.
Web of Science Citations: 1
Abstract

Rationale: Malignant pleural effusion has few options of treatment and drugs administrated by different routes can lead to a less permissive microenvironment for the development of malignant pleural disease. Objectives: To analyze therapies administered intrapleurally in malignant pleural disease and to study EGFR and KRAS mutations in adenocarcinoma. Methods: Mice received LLC cells and were treated intrapleurally with anti-VEGF, anti-EGFR, anti-VEGF+anti-EGFR or saline. Animal survival, weight and mobility, volume, biochemistry and immunology of fluid, gene expression, KRAS and EGFR mutation were evaluated. Results: All animals developed malignant effusion and presented progressive weight loss without difference between groups; however, groups treated with anti-EGFR were more active. No difference in mortality was observed. Temporal increase of volume and inflammatory markers was observed mainly in the untreated group. Gene expression in tumors was overexpressed in VEGF, EGFR and KRAS compared with normal tissue. Mutation in exon 2 of the KRAS gene was observed. Conclusions: Intrapleural Anti-VEGF and/or anti-EGFR reduced volume and inflammatory mediators in pleural fluid. Anti-EGFR and anti-VEGF+anti-EGFR decreased morbidity although without impact on survival. LLC tumors presented KRAS mutation, this could have influenced the action of these therapies. (AU)

FAPESP's process: 13/11148-9 - Biomecular profile of experimental malignant pleural effusion: frequency of mutations and targeted therapies impact
Grantee:Lisete Ribeiro Teixeira
Support Opportunities: Regular Research Grants